Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas B Kepler

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Nature Communications|April 11, 2015
Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunizationJoseph R Francica, Zizhang Sheng, Zhenhai Zhang, et al.
Cell Host & Microbe|September 12, 2014
Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodiesThomas B Kepler, Hua-Xin Liao, S Munir Alam, et al.
The Journal of Clinical Investigation|March 12, 2014
An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1Mattia Bonsignori, Kevin Wiehe, Sebastian K Grimm, et al.
Ebiomedicine|September 11, 2016
Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization SensitivityTodd Bradley, Ashley Trama, Nancy Tumba, et al.
Journal of Virology|November 29, 2019
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and PotencyDavid Easterhoff, Justin Pollara, Kan Luo, et al.
Journal of Virology|August 11, 2017
HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus MacaquesQifeng Han, Wilton B Williams, Kevin O Saunders, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
Immunity|May 18, 2017
Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding LoopEvan M Cale, Jason Gorman, Nathan A Radakovich, et al.
Immunity|December 20, 2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conservedKevin Wiehe, David Easterhoff, Kan Luo, et al.
The Journal of Experimental Medicine|October 12, 2011
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutatedHua-Xin Liao, Xi Chen, Supriya Munshaw, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Nature Communications|April 11, 2015
Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunizationJoseph R Francica, Zizhang Sheng, Zhenhai Zhang, et al.
Cell Host & Microbe|September 12, 2014
Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodiesThomas B Kepler, Hua-Xin Liao, S Munir Alam, et al.
The Journal of Clinical Investigation|March 12, 2014
An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1Mattia Bonsignori, Kevin Wiehe, Sebastian K Grimm, et al.
Ebiomedicine|September 11, 2016
Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization SensitivityTodd Bradley, Ashley Trama, Nancy Tumba, et al.
Journal of Virology|November 29, 2019
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and PotencyDavid Easterhoff, Justin Pollara, Kan Luo, et al.
Journal of Virology|August 11, 2017
HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus MacaquesQifeng Han, Wilton B Williams, Kevin O Saunders, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
Immunity|May 18, 2017
Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding LoopEvan M Cale, Jason Gorman, Nathan A Radakovich, et al.
Immunity|December 20, 2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conservedKevin Wiehe, David Easterhoff, Kan Luo, et al.
The Journal of Experimental Medicine|October 12, 2011
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutatedHua-Xin Liao, Xi Chen, Supriya Munshaw, et al.
Pageof 13